Abstract Number: 2230 • 2018 ACR/ARHP Annual Meeting
Serum Urate Levels in People with Gout on Dialysis – Are We Achieving Treatment Targets?
Background/Purpose: To explore the number of patients on haemodialysis (HD) or peritoneal dialysis (PD) with gout in Canterbury and to determine how many were receiving…Abstract Number: 2231 • 2018 ACR/ARHP Annual Meeting
An Ancestral-Specific Interaction of TRIM46 with a Past-History of Smoking May Influence Gout Risk
Background/Purpose: Gout is caused by an interplay of genetic and environmental factors. Epidemiological and prospective studies suggest that current-smoking may be protective for developing gout…Abstract Number: 2232 • 2018 ACR/ARHP Annual Meeting
Prevalence of Gout in the Surviving U.S. Solid Organ Transplant Population
Background/Purpose: Although incidence and survival are frequent topics within the solid organ transplant (SOT) literature, there are no recent publications on the total size of…Abstract Number: 2233 • 2018 ACR/ARHP Annual Meeting
Activation and Deficiency of Circulating Mucosal-Associated Invariant T Cells in Patients with Gouty Arthritis
Background/Purpose: Mucosal-associated invariant T (MAIT) cells contribute to protection against certain microorganism infections and play an important role in mucosal immunity. Upon antigen recognition, MAIT…Abstract Number: 2234 • 2018 ACR/ARHP Annual Meeting
Liver Safety of Febuxostat Compared with Allopurinol in Gout Patients with Fatty Liver Disease
Background/Purpose: Although febuxostat has been widely used for lowering uric acid levels because of its renal safety compared with allopurinol, data on the hepatic safety…Abstract Number: 2235 • 2018 ACR/ARHP Annual Meeting
Monosodium Urate Deposition Distribution in the Knees, Hands, and Feet of Treated Gout Patients: A Dual-Energy CT Study
Background/Purpose: Prior studies have demonstrated that monosodium urate (MSU) deposits on dual-energy CT (DECT) are commonly found in joints as well as tendons of the…Abstract Number: 2236 • 2018 ACR/ARHP Annual Meeting
Contemporary Comorbidity Burden of Gout and Hyperuricemia in the US during the Past Decade (National Health And Nutrition Examination Survey [NHANES] 2007-2016)
Background/Purpose: Precise estimates of the comorbidity burden of gout and hyperuricemia are critical as their presence has important implications for the treatment of both gout…Abstract Number: 2237 • 2018 ACR/ARHP Annual Meeting
Prevalence of Urate-Lowering Therapy Use and Target Urate Level Achievement Among Gout Patients in the United States (National Health And Nutrition Examination Survey [NHANES] 2007-2014)
Background/Purpose: To determine the latest national prevalence of urate-lowering therapy (ULT) use and achievement of a therapeutic target serum urate level (SUL) in gout patients,…Abstract Number: 2240 • 2018 ACR/ARHP Annual Meeting
Hip Involvement in Patients with Gout: Results of an Ultrasound Study
Background/Purpose: Although considered as uncommon, the hip represents one of the possible targets of gout. To date, hip involvement in patients with gout has been…Abstract Number: 2241 • 2018 ACR/ARHP Annual Meeting
What Can Variation in Clinical Practice Teach Us about Treatment Strategies for Patients with Gout?
Background/Purpose: To improve quality of care for patients with gout, two hospitals in the Netherlands initiated a protocolized gout clinic. One clinic adopted a patient-centred…Abstract Number: 2242 • 2018 ACR/ARHP Annual Meeting
Cardiovascular Outcomes of Treatment with Febuxostat and Allopurinol in Gout Patients with Kidney Disease
Background/Purpose: The Cardiovascular Safety of Febuxostat and Allopurinol in Patients with Gout and Cardiovascular Comorbidities (CARES) trial demonstrated that major cardiovascular (CV) outcomes on febuxostat…Abstract Number: 2244 • 2018 ACR/ARHP Annual Meeting
Comparison of an Interactive Voice Response (IVR) to Smart Phone App to Determine Patient Preference for Reporting Gout Flares
Background/Purpose: Gout flares are a major cause of morbidity and are an important outcome in clinical studies. Significant limitations for timely flare ascertainment exist, and…Abstract Number: 2247 • 2018 ACR/ARHP Annual Meeting
Predictors of End-Stage Renal Disease (ESRD) in Gout Patients and General Population (GP) Controls – a Role for Interstitial Nephritis, Urate Nephropathy?
Background/Purpose: Decreased renal excretion of urate is an established risk factor for hyperuricemia, whereas it is less clear if hyperuricemia or gout predict impaired kidney…Abstract Number: 2248 • 2018 ACR/ARHP Annual Meeting
Genetic Variants Identify Interleukin 37 As an Important Anti-Inflammatory Cytokine in Gout in Humans
Background/Purpose: During a gout flare monosodium urate (MSU) crystals induce, in the presence of a secondary stimulus, acute joint inflammation characterized by the recruitment of…Abstract Number: 2249 • 2018 ACR/ARHP Annual Meeting
Not Just a Swollen Big Toe: Increasing All-Cause Hospitalizations in Patients with Gout in the United States: 1993–2014
Background/Purpose: Gout is a disorder of uric acid metabolism and often presents as acute severe joint pain. However, several recent studies have highlighted systemic complications…
Simple Search Results
Didn't find what you were looking for? Try the Advanced Search »
Didn't find what you were looking for? Try the Advanced Search »